Non-small-cell lung cancer (NSCLC) is a diverse disease with a variety of optimal treatment approaches, including immunotherapy and an array of targeted therapies, each specific to a particular oncogenic driver mutation. The broadening options for the treatment of this disease have made therapeutic decisions more complex, presenting challenges for clinicians who must decide when and how to treat patients, individualize drug regimens, and manage potential adverse events. To optimize outcomes for patients with advanced NSCLC, it is critical that molecular analysis of predictive biomarkers be used to guide treatment decisions, and that severe treatment-related complications are prevented and timely adjustments to therapy are facilitated in response to toxicities once a patient is on therapy. In this video lecture, an expert provides advice on predictive biomarkers, including how to apply them to guide optimal use of targeted and immunotherapies in the care of patients with NSCLC. Additionally, identification and management of adverse events associated with this diverse set of therapies are discussed.
Interactive video lecture
After completing this activity, participants should be better able to:
- Describe predictive biomarkers in NSCLC and their impact on clinical decision-making
- Formulate strategies for appropriate use of targeted therapeutics and immuno-oncology agents in patients with NSCLC
- Apply strategies to identify and manage toxicities associated with novel therapies for NSCLC
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 16, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from Astellas and Pﬁzer; AstraZeneca; Bristol Myers Squibb; Dendreon Pharmaceuticals LLC; Eisai; Epizyme Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Regeneron Pharmaceuticals, Inc. and Sanoﬁ Genzyme; and Seagen Inc. formerly Seattle Genetics.
This activity is supported by an educational grant from Merck & Co., Inc. and Novartis Pharmaceuticals Corporation.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Duma: consulting: AstraZeneca, Boehringer Ingelheim, Inivata, Janssen, Neogenomics, Pfizer.
Ms Sandy: speakers bureau: AstraZeneca, Jazz, Merck, Takeda.
Ms Williams: consulting/speakers bureau: AbbVie, AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 17, 2021
Expiration date: August 16, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 100621O-7J